Advax4 delta inulin combination adjuvant together with ECMX, a fusion construct of four protective mTB antigens, induces a potent Th1 immune response and protects mice against Mycobacterium tuberculosis infection

Tuberculosis (TB) remains a main public health concern and 10.4 million new cases occurred in 2015 around the world. BCG is the only approved vaccine against TB, but has variable efficacy and new vaccines are needed. We developed two new mTB vaccine candidates based on the recombinant fusion protein...

Descripció completa

Dades bibliogràfiques

Autors principals:	Bruno de Paula Oliveira Santos, Monalisa Martins Trentini, Renato Beilner Machado, Mara Rúbia Nunes Celes, André Kipnis, Nikolai Petrovsky, Ana Paula Junqueira-Kipnis
Format:	Artigo
Idioma:	Inglês
Publicat:	Taylor & Francis Group 2017-12-01
Col·lecció:	Human Vaccines & Immunotherapeutics
Matèries:	tuberculosis vaccine adjuvant tb ecmx advax delta inulin
Accés en línia:	http://dx.doi.org/10.1080/21645515.2017.1368598
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!